Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS38 is a potent and selective small molecule inhibitor of Death-associated protein kinase 1 (DAPK1) and Death-associated protein kinase 3 (DAPK3), also known as Zipper-interacting protein kinase (ZIPK). Developed as a chemical probe, HS38 is primarily used in research to investigate the physiological roles of the DAPK family in processes such as apoptosis, autophagy, and actin-cytoskeleton reorganization. Preclinical studies have utilized HS38 to explore the role of DAPK3 in intestinal regeneration and the progression of ulcerative colitis, where its inhibition has been shown to interfere with Hippo-YAP signaling and exacerbate disease severity in animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HS38.